Suppr超能文献

早孕期循环 microRNA 生物标志物预测晚期早产及宫颈缩短。

First Trimester Circulating MicroRNA Biomarkers Predictive of Subsequent Preterm Delivery and Cervical Shortening.

机构信息

Parturition Research Group, Institute of Reproductive and Developmental Biology, Imperial College London, Du Cane Road, London, W12 0NN, UK.

Queen Charlotte's and Chelsea Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London, W12 0HS, UK.

出版信息

Sci Rep. 2019 Apr 10;9(1):5861. doi: 10.1038/s41598-019-42166-1.

Abstract

Preterm birth (PTB) is the leading cause of infant death and disability worldwide. The onset of preterm uterine contractions is preceded by asymptomatic cervical remodelling and ripening, which can be seen on trans-vaginal ultrasound as cervical shortening. This study aimed to identify plasma miRNA biomarkers that predict preterm birth and/or cervical shortening. We collected serial plasma samples from pregnant women prospectively from 12 to 22 weeks gestation. The nCounter miRNA assay was used to identify differentially expressed miRNAs associated with spontaneous PTB and/or cervical shortening (n = 16 term no short, n = 13 preterm, n = 24 short). Predictive values of the miRNA biomarkers were confirmed in an independent validation cohort consisting of 96 women who delivered at term, 14 preterm and 21 early cervical shortening at <20 weeks gestation. Nine miRNAs (hsa-let-7a-5p, hsa-miR-374a-5p, hsa-miR-15b-5p, hsa-miR-19b-3p, hsa-miR-23a-3p, hsa-miR-93-5p, hsa-miR-150-5p, hsa-miR-185-5p and hsa-miR-191-5p) were differentially expressed (P < 0.001) in women subsequently experiencing PTB or cervical shortening. Hsa-miR-150-5p had the strongest ability to predict PTB (AUC = 0.8725) and cervical shortening (AUC = 0.8514). Plasma miRNAs in the first trimester can predict PTB and cervical shortening in women at risk of preterm delivery. This is a key period in pregnancy when early identification of PTB risk allows time to deliver outcome-modifying interventions.

摘要

早产(PTB)是全球婴儿死亡和残疾的主要原因。早产子宫收缩的发生之前是无症状的宫颈重塑和成熟,这可以在阴道超声上看到宫颈缩短。本研究旨在确定预测早产和/或宫颈缩短的血浆 miRNA 生物标志物。我们前瞻性地从 12 至 22 周妊娠的孕妇中收集连续血浆样本。使用 nCounter miRNA 分析鉴定与自发性 PTB 和/或宫颈缩短相关的差异表达 miRNA(n=16 个足月无缩短,n=13 个早产,n=24 个缩短)。在一个由 96 名在足月分娩的妇女、14 名早产和 21 名在<20 周妊娠时发生早期宫颈缩短的妇女组成的独立验证队列中,验证了 miRNA 生物标志物的预测值。9 个 miRNA(hsa-let-7a-5p、hsa-miR-374a-5p、hsa-miR-15b-5p、hsa-miR-19b-3p、hsa-miR-23a-3p、hsa-miR-93-5p、hsa-miR-150-5p、hsa-miR-185-5p 和 hsa-miR-191-5p)在随后经历 PTB 或宫颈缩短的妇女中表达差异(P<0.001)。hsa-miR-150-5p 预测 PTB(AUC=0.8725)和宫颈缩短(AUC=0.8514)的能力最强。在有早产风险的孕妇中,第一孕期的血浆 miRNA 可预测 PTB 和宫颈缩短。这是妊娠的关键时期,早期识别 PTB 风险可以为实施改变结局的干预措施提供时间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6d6/6458157/1dbefddcf5c1/41598_2019_42166_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验